Table of Contents
Lymphoma
Volume 2015 (2015), Article ID 123548, 10 pages
http://dx.doi.org/10.1155/2015/123548
Research Article

Non-Hodgkin Lymphoma in Children with Primary Immunodeficiencies: Clinical Manifestations, Diagnosis, and Management, Belarusian Experience

1Clinical Research Department, Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Borovlyany, 223053 Minsk, Belarus
2Laboratory of Immunology, Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Borovlyany, 223053 Minsk, Belarus
3Department of Pathology, Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Borovlyany, 223053 Minsk, Belarus
4Consultative and Outpatient Department, Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Borovlyany, 223053 Minsk, Belarus
5Oncohematological Department N2, Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Borovlyany, 223053 Minsk, Belarus
6Laboratory of Genetic Biotechnology, Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Borovlyany, 223053 Minsk, Belarus
7Research Department, Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Borovlyany, 223053 Minsk, Belarus
8Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Borovlyany, 223053 Minsk, Belarus

Received 29 September 2014; Accepted 11 January 2015

Academic Editor: Wolfram Klapper

Copyright © 2015 Alina Fedorova et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Chinen, D. Anmuth, A. R. K. Franklin, and W. T. Shearer, “Long-term follow-up of patients with primary immunodeficiencies,” Journal of Allergy and Clinical Immunology, vol. 120, no. 4, pp. 795–797, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. N. F. C. C. de Miranda, A. Björkman, and Q. Pan-Hammarström, “DNA repair: the link between primary immunodeficiency and cancer,” Annals of the New York Academy of Sciences, vol. 1246, no. 1, pp. 50–63, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Tran, J. Nourse, S. Hall, M. Green, L. Griffiths, and M. K. Gandhi, “Immunodeficiency-associated lymphomas,” Blood Reviews, vol. 22, no. 5, pp. 261–281, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Oertel and H. Reiss, Immunosurveillance, Immunodeficiency and Lymphoproliferations, Springer, Heidelberg, Germany, 2002.
  5. A. Reiter, M. Schrappe, M. Tiemann et al., “Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM-90,” Blood, vol. 94, no. 10, pp. 3294–3306, 1999. View at Google Scholar · View at Scopus
  6. S. H. Swerdlow, E. Campo, N. L. Harris et al., WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon, France, 4th edition, 2008.
  7. S. B. Murphy, “Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults,” Seminars in Oncology, vol. 7, no. 3, pp. 332–339, 1980. View at Google Scholar · View at Scopus
  8. A. Reiter, M. Schrappe, W.-D. Ludwig et al., “Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM Group report,” Blood, vol. 95, no. 2, pp. 416–421, 2000. View at Google Scholar · View at Scopus
  9. B. Burkhardt, W. Woessmann, M. Zimmermann et al., “Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma,” Journal of Clinical Oncology, vol. 24, no. 3, pp. 491–499, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. W. Woessmann, K. Seidemann, G. Mann et al., “The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms—a report of the BFM Group Study NHL-BFM95,” Blood, vol. 105, no. 3, pp. 948–958, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Seidemann, M. Tiemann, M. Schrappe et al., “Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90,” Blood, vol. 97, no. 12, pp. 3699–3706, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. M.-C. Le Deley, A. Rosolen, D. M. Williams et al., “Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial,” Journal of Clinical Oncology, vol. 28, no. 25, pp. 3987–3993, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Brugières, M.-C. le Deley, A. Rosolen et al., “Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group,” Journal of Clinical Oncology, vol. 27, no. 6, pp. 897–903, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. J. A. Sparano, J. Y. Lee, L. D. Kaplan et al., “Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma,” Blood, vol. 115, no. 15, pp. 3008–3016, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. W. Al-Herz, A. Bousfiha, J.-L. Casanova et al., “Primary immunodeficiency diseases: an update on the classification from the International Union of immunological societies expert committee for primary immunodeficiency,” Frontiers in Immunology, vol. 5, article 162, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Booth, K. C. Gilmour, P. Veys et al., “X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease,” Blood, vol. 117, pp. 53–62, 2011. View at Publisher · View at Google Scholar
  17. K. Seidemann, M. Tiemann, and G. Henze, “Therapy for non-Hodgkin lymphoma in children with primary immunodeficiency: analysis of 19 patients from the BFM trials,” Medical and Pediatric Oncology, vol. 33, no. 6, pp. 536–544, 1999. View at Publisher · View at Google Scholar
  18. C. Sandoval and M. Swift, “Treatment of lymphoid malignancies in patients with ataxia-telangiectasia,” Medical and Pediatric Oncology, vol. 31, no. 6, pp. 491–497, 1998. View at Publisher · View at Google Scholar
  19. B. Dembowska-Baginska, D. Perek, A. Brozyna et al., “Non-Hodgkin lymphoma (NHL) in children with Nijmegen Breakage syndrome (NBS),” Pediatric Blood and Cancer, vol. 52, no. 2, pp. 186–190, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Bienemann, B. Burkhardt, S. Modlich et al., “Promising therapy results for lymphoid malignancies in children with chromosomal breakage syndromes (Ataxia teleangiectasia or Nijmegen-breakage syndrome): a retrospective survey,” British Journal of Haematology, vol. 155, no. 4, pp. 468–476, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. J. T. Sandlund, M. M. Hudson, W. Kennedy, M. Onciu, and M. B. Kastan, “Pilot study of modified LMB-based therapy for children with ataxia-telangiectasia and advanced stage high grade mature B-cell malignancies,” Pediatric Blood and Cancer, vol. 61, no. 2, pp. 360–362, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Gładkowska-Dura, K. Dzierzanowska-Fangrat, W. T. Dura et al., “Unique morphological spectrum of lymphomas in Nijmegen breakage syndrome (NBS) patients with high frequency of consecutive lymphoma formation,” The Journal of Pathology, vol. 216, no. 3, pp. 337–344, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. M. L. Gulley, C.-L. Chen, and N. Raab-Traub, “Epstein-Barr virus-related lymphomagenesis in a child with Wiskott-Aldrich syndrome,” Hematological Oncology, vol. 11, no. 3, pp. 139–145, 1993. View at Publisher · View at Google Scholar · View at Scopus
  24. L. Dupré, G. Andolfi, S. G. Tangye et al., “SAP controls the cytolytic activity of CD8+ T cells against EBV-infected cells,” Blood, vol. 105, no. 11, pp. 4383–4389, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Bagley, M. L. Cortes, X. O. Breakefield, and J. Iacomini, “Bone marrow transplantation restores immune system function and prevents lymphoma in Atm-deficient mice,” Blood, vol. 104, no. 2, pp. 572–578, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Kawa, T. Okamura, M. Yasui, E. Sato, and M. Inoue, “Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/NK-cell lymphoproliferative disease,” Critical Reviews in Oncology/Hematology, vol. 44, no. 3, pp. 251–257, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. L. L. Williams, C. M. Rooney, M. E. Conley, M. K. Brenner, R. A. Krance, and H. E. Heslop, “Correction of Duncan's syndrome by allogeneic bone marrow transplantation,” The Lancet, vol. 342, no. 8871, pp. 587–588, 1993. View at Publisher · View at Google Scholar · View at Scopus
  28. M. H. Albert, A. R. Gennery, J. Greil et al., “Successful SCT for Nijmegen breakage syndrome,” Bone Marrow Transplantation, vol. 45, no. 4, pp. 622–626, 2010. View at Publisher · View at Google Scholar · View at Scopus